Telomir Pharmaceuticals, Inc. (TELO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Telomir Pharmaceuticals, Inc. on June 15, 2026. The Company is an emerging growth company incorporated in Florida, with its principal executive offices in Miami. The filing primarily addresses a Regulation FD disclosure regarding the publication of preclinical data.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on scientific developments rather than financial performance.
Material Changes and Scientific Developments
- Peer-Reviewed Publication: The Company announced the publication of preclinical data in Biomedicine & Pharmacotherapy regarding its lead candidate, Telomir-Zn.
- Study Findings: The study, titled "Telomir-Zn Restores Glucose Homeostasis and Reduces Insulin Resistance in a Diet-Induced Zebrafish Model of Type 2 Diabetes," reported dose-dependent improvements in fasting blood glucose, glucose tolerance, fasting insulin levels, and insulin resistance (HOMA-IR).
- Mechanism of Action: The findings support Telomir-Zn's mechanism through the modulation of intracellular metal homeostasis.
- Publication Frequency: This marks the Company's second peer-reviewed publication in 2026 supporting the biological mechanism of Telomir-Zn.
- Clinical Status: Telomir-Zn has received Investigational New Drug (IND) clearance from the FDA for the Phase 1/2 clinical trial (TELO-001) in patients with advanced or metastatic triple-negative breast cancer.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future financial outlook, or a discussion of risks and contingencies beyond the standard disclaimer that the information is furnished and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for additional details on the study methodology and limitations.
- Confirm the current status and enrollment progress of the TELO-001 Phase 1/2 clinical trial for triple-negative breast cancer.
- Review the Company's most recent 10-Q or 10-K filing for up-to-date financial metrics, cash runway, and liquidity position, as this 8-K does not contain such data.
- Assess the relevance of the zebrafish model findings to the Company's primary clinical indication (breast cancer) versus the metabolic effects observed in the study.